NO20092099L - DMAE as sole agent for the treatment of mild cognitive impairment - Google Patents

DMAE as sole agent for the treatment of mild cognitive impairment

Info

Publication number
NO20092099L
NO20092099L NO20092099A NO20092099A NO20092099L NO 20092099 L NO20092099 L NO 20092099L NO 20092099 A NO20092099 A NO 20092099A NO 20092099 A NO20092099 A NO 20092099A NO 20092099 L NO20092099 L NO 20092099L
Authority
NO
Norway
Prior art keywords
dmae
treatment
cognitive impairment
mild cognitive
sole agent
Prior art date
Application number
NO20092099A
Other languages
English (en)
Norwegian (no)
Inventor
Pierre Fabre
Christophe Przybylski
Bruno Dubois
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20092099L publication Critical patent/NO20092099L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20092099A 2006-10-31 2009-05-28 DMAE as sole agent for the treatment of mild cognitive impairment NO20092099L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609548A FR2907679B1 (fr) 2006-10-31 2006-10-31 Utilisation de dmae pour le traitement de deficit cognitif leger
PCT/EP2007/061737 WO2008053011A1 (fr) 2006-10-31 2007-10-31 Le dmae en tant qu'agent unique pour le traitement de deficit cognitif leger

Publications (1)

Publication Number Publication Date
NO20092099L true NO20092099L (no) 2009-07-17

Family

ID=38050144

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092099A NO20092099L (no) 2006-10-31 2009-05-28 DMAE as sole agent for the treatment of mild cognitive impairment

Country Status (18)

Country Link
US (1) US8207218B2 (https=)
EP (1) EP2083814B1 (https=)
JP (1) JP2010508253A (https=)
KR (1) KR20090082428A (https=)
CN (1) CN101528220A (https=)
AR (1) AR063764A1 (https=)
AU (1) AU2007316137A1 (https=)
BR (1) BRPI0718263A2 (https=)
CA (1) CA2667983A1 (https=)
FR (1) FR2907679B1 (https=)
IL (1) IL198463A0 (https=)
MA (1) MA30925B1 (https=)
MX (1) MX2009004682A (https=)
NO (1) NO20092099L (https=)
RU (1) RU2009120137A (https=)
TN (1) TN2009000159A1 (https=)
WO (1) WO2008053011A1 (https=)
ZA (1) ZA200903626B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150157046A1 (en) * 2013-12-10 2015-06-11 Lifewave, Inc. Nutritional product composition for the mind

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002320251A1 (en) * 2001-07-05 2003-01-21 Vital Basics, Inc. Compositions for improving mental performance
US20060211721A1 (en) * 2005-03-21 2006-09-21 Roberts Alan R Nutraceutical formulation of a cognitive enhancement system

Also Published As

Publication number Publication date
IL198463A0 (en) 2010-02-17
US20090298908A1 (en) 2009-12-03
BRPI0718263A2 (pt) 2014-01-07
CN101528220A (zh) 2009-09-09
FR2907679A1 (fr) 2008-05-02
MA30925B1 (fr) 2009-11-02
CA2667983A1 (fr) 2008-05-08
TN2009000159A1 (fr) 2010-10-18
AU2007316137A1 (en) 2008-05-08
US8207218B2 (en) 2012-06-26
AR063764A1 (es) 2009-02-18
FR2907679B1 (fr) 2009-10-30
WO2008053011A1 (fr) 2008-05-08
KR20090082428A (ko) 2009-07-30
RU2009120137A (ru) 2010-12-10
EP2083814A1 (fr) 2009-08-05
MX2009004682A (es) 2009-09-28
JP2010508253A (ja) 2010-03-18
ZA200903626B (en) 2010-07-28
EP2083814B1 (fr) 2013-03-20

Similar Documents

Publication Publication Date Title
DK1807072T3 (da) Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
IL195030A (en) Dpp iv inhibitor formulations
BRPI0908421C1 (pt) solução estável de um composto farmacêutico
MX2008012017A (es) Pirazoles como inhibidores de 11-beta-hsd1.
CL2008003003A1 (es) Mezcla binaria que comprende 2-amino-2-[2-(4-octil-fenil)etil]propano-1,3-diol (fty720) y un excipiente seleccionado de lactosa, hpmc, hpc, crospovidona, croscarmelosa de sodio, almidon y dioxido de silicio coloidal, y su uso para el tratamiento de enfermedades autoinmunes, entre otras.
DK2029529T3 (da) Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
WO2008063933A3 (en) Pak modulators
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
NO20075920L (no) Assosiasjon mellom ferroquin og et artemisininderivat for behandling av malaria
NO20080936L (no) Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NI200900052A (es) Heterocíclicos derivados de los inhibidores de metaloproteasa
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application